IDEMIA
15.10.2018 16:55:43 CEST | Business Wire | Press release
The supervisory board of IDEMIA, the global leader in Augmented Identity, has appointed Yann Delabrière to be Chief Executive Officer with immediate effect taking over from Didier Lamouche who has resigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005635/en/
One year after the successful coming together of Oberthur Technologies (OT) and Safran I&S (Morpho) that gave rise to IDEMIA, Yann Delabrière will be charged with overseeing a new phase in the Group’s growth.
Yann Delabrière, who previously served as CEO of Faurecia followed by CEO of Zodiac Aerospace, was appointed IDEMIA’s supervisory board chairman in January 2018. Since then he has gained in-depth understanding of the Company’s operations and people. IDEMIA will now look to benefit from Yann’s extensive international managerial experience.
Yann Delabrière stated: “I am delighted that the Supervisory Board is entrusting me with this new role, and am excited to be leading IDEMIA as it enters the next phase of its development. IDEMIA has developed cutting-edge technologies and services leveraging artificial intelligence, biometrics and cryptography. This makes IDEMIA a major technological player in the fields of identity management and authentication or security of payments. I have witnessed IDEMIA’s growth potential first hand and believe it is excellently poised to continue to consolidate its position as the leader in the sector”
Didier Lamouche added: “During almost six years at the helm of Oberthur Technologies (OT) then IDEMIA, I am extremely proud to have contributed to building, with the teams, what has become the global leader of Augmented Identity. Together, we achieved numerous commercial successes and brought to market significant innovations, not only in the financial sector, but also with access solutions combining biometrics and remote secure communication. The successful integration of both companies, OT and Morpho, fueled by solid operational results, opens a bright future to IDEMIA and all its employees. I wish them all every success.”
Notes to Editors
About Yann Delabrière
Yann Delabrière is a graduate of the Ecole
Normale Supérieure, the Ecole Nationale d’Administration (the French
National School of Administration) and has a post-graduate degree in
mathematics. He began his career at the Committee of Public Accounts
before working in the cabinet office of the Foreign Trade Ministry. He
then worked as Financial Director of COFACE (Compagnie Française
d’Assurance pour le Commerce Extérieur, a French export credit agency)
and for the Printemps Group. In 1990, he joined the PSA Peugeot Citroën
Group as Chief Financial Officer and, in this role, became a member of
the automaker’s Executive Committee in 1998, and Chairman and CEO of the
Group’s consumer finance unit, Banque PSA Finance. Yann Delabrière was
appointed as Chairman and Chief Executive Officer of Faurecia in 2007.
He was also Chairman of the Executive Board of Zodiac Aerospace between
June 2017 and February 2018. He has been a member of the Board of
Directors of Cap Gemini from 2004 to May 2018, a member of the Board of
Directors of Société Générale from 2012 to 2016, and member of the Board
of Directors of Alstom since March 2017. He has headed IDEMIA’s
Supervisory Board since January 2018.
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to provide a secure environment enabling citizens and
consumers alike to perform their daily critical activities (such as pay,
connect, travel and vote), in the physical as well as digital space.
Securing
our identity has become mission critical in the world we live in today.
By standing for Augmented Identity, we reinvent the way we think,
produce, use and protect this asset, whether for individuals or for
objects. We ensure privacy and trust as well as guarantee secure,
authenticated and verifiable transactions for international clients from
Financial, Telecom, Identity, Public Security and IoT sectors.
OT
(Oberthur Technologies) and Safran Identity & Security (Morpho) have
joined forces to form IDEMIA. With close to $3 billion in revenues and
14,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005635/en/
Contact:
IDEMIA Press Hanna Sebbah: idemia@havas.com +33 (0)6 63 73 30 30
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom